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Tuberculosis in HIV-infected children in the UK and Ireland: incidence, risk factors and outcomes 
 
ABSTRACT 
Background: Tuberculosis (TB) remains the most common serious co-infection in people living with 
HIV worldwide, but little is known about its incidence in HIV-infected children in high-resource 
settings with low tuberculosis prevalence We aimed to assess the incidence and prevalence of 
tuberculosis in children with HIV living in the UK and Ireland to understand rates, risk factors and 
outcomes of the diseases in this group. 
Methods:  We did an analysis or children enrolled in CHIPS, an observational multicentre cohort of 
children receiving HIV care in the UK and Ireland. We assessed characteristics and prevalence of 
tuberculosis at baseline, measured incidence of disease through the follow-up period using the 
CHIPS database, and calculated associated risk factors in these children with multivariable logistic 
and Cox regression models.  
Findings: Between Jan 1, 1996 to Sept 18, 2014, data for 1848 children with 14761 years of follow-
up were reported to CHIPS.  57 (3%) children were diagnosed with tuberculosis: 29 children had 
tuberculosis at presentation (prevalent tuberculosis) and 29 had the disease diagnosed during 
follow-up (incident tuberculosis), including one child with recurrent tuberculosis events.  Median age 
at TB diagnosis was 9years (IQR 5, 12).  25 children (43%) had pulmonary tuberculosis, 24 (41%) 
extrapulmonary with or without pulmonary involvement, and the remainder (n=9, 16%) had 
unspecified-site tuberculosis.  The overall incidence rate was 196 cases per 100000 person-years 
(95%CI 137-283).  In our multivariable model, tuberculosis at presentation was associated with more 
severe WHO immunological stage at baseline (odds ratio 0.25, 95% CI 0.08-0.74; p=0.0331; for none 
vs severe) and being born abroad (odds ratio 0.28, 0.10-0.73; p=0.0036; for UK and Ireland vs 
abroad). Incident tuberculosis was associated with time-updated more severe WHO immunological 
stage (hazard ratio 0.15, 95% CI 0.06-0.41; p=0.0056; for none vs severe) and older age at baseline 
(1.11, 0.47-2.63; p=0.0027; for age >10 years vs 5-9 years).  
Interpretation: Tuberculosis rates in HIV-infected children in the UK and Ireland were higher than 
those reported in the general paediatric population. Further study is warranted of tuberculosis 
screening and preventive treatment for children at high-risk of this disease to avoid morbidity and 
mortality in this population.  
Funding: NHS England, PENTA Foundation 
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RESEARCH IN CONTEXT 
 
Evidence before this study 
We searched PubMed using the terms “HIV”, “tuberculosis”, and “children” for studies published in 
English before June 1, 2015.  Only four studies reported tuberculosis rates in HIV-infected children in 
high-resource countries with low TB prevalence. Two studies from 2000 and 2001 reported on 
tuberculosis in HIV-infected children in the USA; however, data were collected in 1989-1998, before 
combination antiretroviral treatment (ART) was widely available). The other two studies were 
subject to selection bias: the 2012 study in Spain analysed tuberculosis rates in HIV-infected children 
who had been admitted to hospital, and the 2008 study from the UK was restricted to HIV infected 
children attending a single tertiary clinic in London.  
 
Added value of this study 
To our knowledge, this is the first nationwide study to assess the prevalence and incidence of 
tuberculosis in HIV-infected children in the ART era in a low tuberculosis prevalence setting.  We 
show that tuberculosis rates in HIV-infected children in the UK and Ireland are markedly higher than 
those in the general paediatric population. In adjusted analysis, risk factors for incident TB in 
children after entry to HIV care were older age at baseline (older than 5 years), and severity of 
immunological status at time of follow-up appointment.  
 
Implications of all the available evidence 
Our findings highlight the need for evaluation of screening practices and implementation of 
preventive tuberculosis treatment for HIV-infected children living in high-resource countries. Future 
research should include record linkage with the national tuberculosis databases, which would permit 
a direct comparison of incidence between children with HIV and those without. 
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Introduction 
The UK and Ireland are classified as countries with low tuberculosis  incidence , with rates  between 
7.3 and14·4 cases per 100000 population.1,2 Three-quarters of cases in the UK occur in adults born 
abroad, with most in settled migrants who are diagnosed more than two years after entering the UK.  
By contrast, most children diagnosed with tuberculosis are born in the UK, reflecting continuing 
transmission within the country.  In  European Union and European Economic Area countries, 
tuberculosis notification rates in children younger than  15 years has decreased from 5.1 to 3.3 per 
100000 population in the past decade.1  The tuberculosis rate in UK-born children ranged from 2·0 to 
3·1 cases per 100000 population, with substantially higher rates in black African (12-30cases per 
100000) and Indian (11 -17cases per 100000) ethnic groups.2,3  The highest rate of 64·8 per 100000, 
was reported among black African children living in London.4 
 
Worldwide, tuberculosis remains the most common serious co-infection in people living with HIV, 
despite a substantial decrease in incidence of tuberculosis after the scale-up of antiretroviral therapy 
(ART).  Although ART reduces the incidence of tuberculosis, it does not completely restore the 
functional immune response against the disease,5,6 and higher rates continue to be recorded in HIV-
infected adults on ART as compared with the general population in both high and low tuberculosis 
incidence countries.7–11  Tuberculosis still accounts for a quarter of deaths in people with HIV, with 
the highest burden in sub-Saharan Africa.12  In Western Europe, tuberculosis is the third most 
common AIDS-defining illness in HIV-infected adults.13 
 
Incidence of tuberculosis in HIV-infected children in low-resource settings has been reported to be 
between 830 cases and 17500 cases per 100000 person-years,14-18 with rates varying widely because 
of different burden of the disease ,uptake of HIV testing, and difficulties in diagnosis of tuberculosis 
in children. Few equivalent data are available in countries with low prevalence of tuberculosis.  In 
2000, two studies reported rates of tuberculosis in children in the USA, but these studies were done 
before ART was widely available and therefore the results are not generalizable to the current 
situation.19,20 One study in Spain reported tuberculosis rates in hospitalised HIV-infected children 
during 1997–2008 to be 15·3 per 1000 hospital admission years, eight-fold higher than that  in 
children without HIV.  However this rate may be an overestimate because the study was restricted 
to children requiring hospitalisation.21 A second study, based in a large clinic in London, reported 
that 5.5% of HIV-infected children were diagnosed with tuberculosis over the 15-year period of 
1991–2006,22 although this might reflect the higher overall tuberculosis incidence rate in London and 
in key groups. 
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In this study, we calculated the prevalence and incidence of tuberculosis in HIV-infected children 
living in the UK and Ireland who are registered in the nationwide Collaborative HIV Paediatric Study 
(CHIPS) and assessed risk factors associated with tuberculosis co-infection.   
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Methods 
CHIPS is an observational multi-centre cohort study of children receiving HIV care in the UK and 
Ireland.  All infants born to HIV-infected women and children aged younger than 16 years diagnosed 
with HIV in the UK and Ireland, irrespective of their place of birth, are reported to the National Study 
of HIV in Pregnancy and Childhood (NSHPC). Once HIV infection is confirmed and the child receives 
care at a centre participating in CHIPS (56 centres as of June, 2015) throughout the IK and Ireland, 
annual follow-up data are collected while in paediatric HIV care, as described online 
(www.chipscohort.ac.uk).23,24 Demographic, clinical, laboratory, and ART-related data have been 
collected since April 2000, with data from 1996 retrospectively obtained.  Both NSHPC and CHIPS 
have received ethics approval from the National Health Service.   
 
Definitions 
We obtained date for prevalent  tuberculosis ( tuberculosis at presentation), defined as the disease 
diagnosed 30 days before or after  entry to HIV care in the UK/Ireland, and incident tuberculosis  ( 
tuberculosis during follow-up) defined as  the disease diagnosed  more than 30 days after entry to 
HIV care.  Additionally, we obtained data for tuberculosis before entry to HIV care, defined as 
patient-reported or documented disease more than 30 days before presentation to HIV care.  
The date of first presentation to an HIV clinic in the UK and Ireland was defined as earliest of first 
clinic visit date, first ART initiation, or date of first CD4 cell count or viral load test; those missing an 
entry date were excluded from analysis. Children with no reported clinic visit for 24 months or more 
(to allow for reporting delays) were considered lost to follow-up. 
 
All events classified as category B or C by the US Centers for Disease Control (CDC), hospital 
admissions, and deaths are routinely reported in the HCIPS database. Events documented as 
tuberculosis -related were reviewed by an independent clinician (AT), whereas those documented as 
suspected TB were checked with the clinics. Latent tuberculosis entered in error and events which 
were subsequently ruled out by the attending clinicians as not tuberculosis were excluded from 
further analysis. Tuberculosis events were reported as either definitive (supported by microscopy, 
histology, cytology, culture, antigen detection or molecular tests) or presumptive (characteristic 
clinical presentation, supported by other investigations and after exclusion of other causes in the 
differential diagnosis).   Tuberculosis clinical forms were categorised by site of infection as 
pulmonary only, extrapulmonary (with and without pulmonary involvement) or unspecified site.  
Recurrent tuberculosis events reported within 12-months of each other were assumed to be a 
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relapse and considered as one event.  Deaths were classified as tuberculosis -related when 
tuberculosis was one of the reported underlying causes of death. 
 
We categorised tuberculosis events into the following three categories: less than 4 months, 4-12 
months and more than 12 months after initiation or restart of ART. The less than 4 month cut-off 
was chosen based on the upper range of the reported median time from start of ART to tuberculosis 
associated immune reconstitution inflammatory syndrome (IRIS) diagnosis in children.25 Children on 
ART for 1 day or longer at time of tuberculosis diagnosis were classified as receiving ART, those who 
were off all antiretroviral drugs for longer than 30 days were classified as off-ART (previously 
treated). HIV-1 RNA virological suppression was defined as less than 400 copies per mL to allow for 
historical variation in assay lower limit of detection.   
 
Statistical analyses 
We describe baseline characteristics of children at time of presentation to HIV care by tuberculosis 
status Characteristics of children with tuberculosis at presentation or during follow-up were 
compared with those with no tuberculosis with use of the 𝜒2test for categorical variables (or Fisher’s 
exact test when numbers were lower than 5), and Wilcoxon’s rank-sum test for continuous variables. 
 
For the analysis of TB incidence, children with tuberculosis before entry to HIV care were considered 
at risk 12 months after their tuberculosis diagnosis date, based on the assumption that they received 
TB treatment for 6-12 months depending on the clinical form and extent of the disease. Those 
without tuberculosis at presentation to HIV care were at risk from 31 days after enrolment. Children 
were censored at their first tuberculosis diagnosis after entry to HIV care, last clinic visit, date of 
transfer to adult care or death.  Incidence of tuberculosis during follow-up was calculated overall as 
cases per 100000 person-years and by key risk factors. 
 
Potential risk factors for tuberculosis include clinical status (pre-AIDS vs AIDS), viral load (VL) and 
WHO immunological stage at entry to HIV care, defined as the nearest measurement to the date of 
entry (up to 90 days after presentation). HIV-associated immunodeficiency for age was classified 
asnone, mild, advanced or severe as per WHO 2007 classification.26 This was chosen as it reflects 
age-adjusted risk of progression to AIDS or death.27 
 
To assess factors associated with having tuberculosis at presentation to HIV care, we used 
multivariable stepwise logistic regression models that included the following baseline variables: sex, 
9 
 
age, place of birth, ethnic origin, region, calendar year, AIDS status, viral load and WHO 
immunological stage at presentation.  To assess factors associated with incident tuberculosis  during 
follow –up we plotted Cox survival models with the above parameters plus time-updated 
immunological stage, ART status (off ART, on ART for less than 4 months, 4-12 months or more than 
12 months), and viral load (per 0.5 log10 increase and viral load <400 copies per mL as proxy of 
effective ART).  Variables with p<0.15 in this univariable analyses were included in a multivariable 
models, and backwards selection (exit probability p=0·1) was used to identify those with the 
strongest association.  Statistical analyses were performed using Stata version 13·1. 
 
Role of the funding source 
The funders of this study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding author had full access to all the data in 
the study and had final responsibility for the decision to submit for publication. 
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Results 
Of 2265 children diagnosed with HIV and reported to NSHPC between Jan 1, 1996 to Sept 18, 2014, 
1907 (84%) were listed in CHIPS, of whom 1848 (97%) had a known date of presentation to HIV care 
and were included in this analysis.  The median duration of follow-up after entry to HIV care was 8·1 
(IQR 4·1-11·8) years, with a total of 14761 person-years of follow-up.  As of Sept 18, 2014, 97 (5%) 
children had died, 98 (5%) left the country, 102 (6%) had been lost to follow up, 635 (34%) had 
transferred to adult care, 4 (<1%) had transferred to another centre and 912 (49%) remain in follow 
up in paediatric care.  Among those currently in follow up in paediatric care the median age at last 
clinic visit was 13.4 years (IQR 10.0-15.7). Among those transferred to adult care, the median age at 
last visit was 17.5 years (IQR 16.6-18.3). 
 
Fifty-seven (3%) children were diagnosed with 58 tuberculosis events. During follow up, 29 children 
had tuberculosis at presentation and 29 had incident tuberculosis, including one child with recurrent 
tuberculosis events (Figure 1).  Additionally, 39 (2%) children were reported to have had tuberculosis 
pre-entry to HIV care, of whom two had recurrent disease at presentation and one developed the 
disease during follow-up. Of 1831 CDC classified events reported at or after presentation, 52 (2%) 
were tuberculosis -related, of which 30 (58%) were stage B and 22 (42%) were stage C.  Of these 52 
TB-related CDC events, 21 were reported as definitive, 16 as presumptive and 15 as unspecified. An 
additional five tuberculosis events in five children were captured through tuberculosis -related 
hospital admissions (no CDC classified event reported). Overall, 64% (37 of 58) of tuberculosis events 
required hospitalisation, representing 1% of the total 3738 hospitalisations reported in the CHIPS 
cohort during this time period. Of the 97 deaths reported in CHIPS during paediatric care, five (5%) 
were probably tuberculosis -related: one died with disseminated tuberculosis and four with 
tuberculosis meningitis (case-fatality rate 5 [9%] of 57).  Three of these children were diagnosed with 
tuberculosis at presentation and two had incident tuberculosis during follow-up.  All were severely 
immunocompromised or had other AIDS-indicator disorders at time of death.  
 
At time of presentation to HIV care, children diagnosed with tuberculosis (at presentation or during 
follow-up) were older (p<0·0001) than those with no tuberculosis (table 1). . Most children with 
tuberculosis at presentation and diagnosis during follow up were born abroad. Most cases of  
tuberculosis occurred in black African children (table1): no tuberculosis cases were diagnosed in 
white children. None of the children with tuberculosis at presentation and only one with 
tuberculosis during follow-up had ever received ART, whereas more than a tenth of those who had 
no tuberculosis had initiated ART before entry to HIV care in UK and Ireland (table 1). 
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Children with tuberculosis at presentation were younger at diagnosis than children who developed 
the disease during follow-up (p=0·0110; table 2). Immunological stage did not differ between the 
two groups (p=0·2323), although children with tuberculosis at presentation had higher viral load at 
the time of diagnosis (p=0.0003). Of the 58 children diagnosed with tuberculosis, 25 (43%) had 
pulmonary tuberculosis only, 24 (41%) had extrapulmonary disease (with or without pulmonary 
involvement), and the remainder (nine [16%]) had unspecified disease (table2).   
 
Among children with tuberculosis at presentation (n=29), three were diagnosed with HIV and TB 
concurrently (within one day), and 20 children presented with tuberculosis before HIV diagnosis. Of 
those with tuberculosis during follow-up, the median time from presentation to HIV care to first 
tuberculosis event was 18 months (IQR 7·0-59·7). Recurrent tuberculosis within the study period was 
reported in one child who had tuberculosis of intra-thoracic lymph nodes at presentation (clinically 
diagnosed) and pulmonary tuberculosis (microbiologically confirmed) 9 years later. 
 
Overall, 39 (67%) tuberculosis events occurred in children who were ART naïve (n=37) or off-ART 
(n=2) at time of TB diagnosis; 35 children initiated or re-started ART at a median of 2·9 (IQR 0·7 -
13·7) months after their diagnosis with tuberculosis (Table 2). Of the four children who did not 
initiate ART, one left the country, one was lost to follow-up, one transferred to adult care and one 
died a month after diagnosis. The remaining 19 (33%) events recorded during follow-up were noted 
at a median 14·3 months (IQR 6·2-44·0) after ART initiation. Five patients had changes to their ART 
regimens within 6 months of their tuberculosis event report. None had conventional substitutions to 
avoid or minimise drug interactions with anti-tuberculosis treatment; only one had an increase of 
nevirapine dose and none had extra ritonavir added.  
 
In multivariable analysis of factors associated with tuberculosis prevalence at presentation to HIV 
care, the only factors independently associated with diagnosis were being born abroad (odds ratio 
for born in the UK or Ireland vs abroad 0.28, 95% CI 0.10-0.73) and severe WHO immunological stage 
at presentation (0.25, 0.08-0.74 for stage none vs severe; table 3).   
 
The overall tuberculosis incidence rate during follow-up in HIV care was 196 cases per 100000 
person-years (95% CI 137-283In univariable analyses, factors associated with incident tuberculosis 
during follow-up were having been born abroad, black African ethnicity, older age (both baseline 
and time-updated), more severe immunosuppression status (time-updated),  higher viral load (time 
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updated copies per mL) and time on ART of less than 4 months (table 4).  After adjustment in 
multivariable analysis, older age at presentation (hazard ratio 1.11, 0.47-2.63, p=0.0027; for >10 
years vs 5-9 years) and more severe current WHO stage immunological status (hazard ratio 0.15, 
95% CI 0.06-0.41; p=0.0056; for none vs severe) remained independent predictors of tuberculosis 
diagnosis during follow up.   
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Discussion 
In the UK and Ireland (as in many other European countries), HIV status is not reported at 
tuberculosis notification to the national surveillance programme, and paediatric HIV-TB record 
linkage has not been established. Therefore the tuberculosis incidence rates in HIV-infected children 
can be estimated only with use of data from national HIV cohorts.  To our knowledge, this is the first 
comprehensive analysis of tuberculosis incidence and associated risk factors in HIV-infected children 
in a high-income country with low tuberculosis prevalence. The CHIPS cohort had 84% coverage for 
all children receiving HIV care in the UK/Ireland from 1996 onwards; this coverage has approached 
100% in recent years,24 with nearly 15,000 person-years of follow-up, and so it is highly 
representative of the HIV-infected paediatric population in the UK and Ireland.  
 
Our results suggest that tuberculosis in HIV-infected children in the UK and Ireland affects 3% of the 
entire cohort, with half of all tuberculosis cases diagnosed at presentation to HIV care. This is similar 
to reports from adult studies in western Europe.11,28 Nearly half (49%) of specified tuberculosis cases 
in our cohort were extrapulmonary, with or without pulmonary involvement, with a high proportion 
of severe extrapulmonary tuberculosis cases, including central nervous system disease in 16%. In 
comparison, the data collected through the British Paediatric Surveillance Unit (BPSU) in the UK and 
Ireland showed that overall extrapulmonary tuberculosis comprise 60% of all tuberculosis forms in 
the general paediatric population, with most forms being hilar lymphadenopathy (i.e. non-severe 
tuberculosis); disease in the central nervous system was diagnosed only in 6% of these cases.29 
Studies from areas with high tuberculosis and HIV-prevalence suggest that HIV-infected children 
have more frequent disseminated tuberculosis,30,31 and severe pulmonary tuberculosis.32  Clinical 
spectrum is likely to depend  on the degree of immune deficiency, with severe forms more common 
in children with advanced HIV.33 A larger study should investigate whether this excess of severe 
tuberculosis disease still occurs in children with none or mild immunodeficiency. Although only 5 
tuberculosis related deaths were noted in CHIPS in the 18-year study period, case-fatality rate was 
nearly 5 times higher than that reported in the BPSU study (9% vs 2%).  Additionally, this was not 
that dissimilar with results from high-TB settings reporting 3.3-11.7% case-fatality rate in HIV-
infected children.14,31,34,35  
    
We report an overall incidence of tuberculosis of 196 cases per 100000 person-years during follow-
up in HIV care. This is much lower than that in countries with a high tuberculosis  burden,  for which 
rates vary from 830 per 100000 to 17500 per 100000,14-18 reflecting higher exposure and higher 
proportion of vulnerable (malnourished and severely immunocompromised) children.  Almost all 
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children with incident tuberculosis in CHIPS were of black African ethnicity (89%) and more than half 
resided in London.  Tuberculosis incidence in HIV-infected children in the ART era seems to remain 
substantially higher than that in the general paediatric population,2,3 and more than triple the 
reported rate among black African children in London.4 Similar results that show increased rates of 
tuberculosis in HIV-infected adults compared with the general population have been reported across 
Europe, despite widespread access to ART.10,11,28,36,37 Furthermore, tuberculosis events in HIV-
infected children in the UK and Ireland would have contributed towards the incidence estimate in 
the general paediatric population; therefore the true incidence in the HIV-uninfected paediatric 
population is likely to be even lower. Of note, there were no tuberculosis events reported in white 
children with HIV in the UK and Ireland, reflecting national trends of higher incidence in black and 
Asian ethnic origin communities, as well as the small proportion (9%) of white children in CHIPS.  
 
The reasons for higher rates of tuberculosis in HIV-infected children than in uninfected children in 
this low prevalence setting are likely to be multifactorial. First, HIV-infected children are likely to 
have higher risk of tuberculosis -exposure because of higher prevalence of the disease TB in HIV-
infected close family members and, for those whose families came from abroad (mostly from sub-
Saharan Africa), due to greater contact with communities from countries with a high tuberculosis 
burden.  Secondly, immune dysfunction which is likely to be present despite ART, predisposes to 
increased progression to tuberculosis infection and subsequent disease. Indeed, 
immunosuppression and black African ethnicity were independently associated with incident 
tuberculosis in our univariable analysis, and immunosuppression in our multivariable analysis, and 
reported in several adult cohorts on ART in Europe.10,11,28,36,37 As shown in adults,10,28 tuberculosis 
events increase during the first few months of ART initiation in children, which is likely to be caused 
by ART unmasking subclinical tuberculosis as a manifestation of IRIS. 
 
Furthermore, children who were older at presentation to HIV care (age older than 5 years) were at 
higher risk of developing tuberculosis during follow-up than younger children, and this might partly 
reflect the reduced capacity for immune restoration in children who initiate ART at older ages.38 A 
substantially lower rate of incidence was shown in children on ART for longer than 12-months and in 
those with suppressed viral load (<400 copies per mL; a proxy of effective ART) in univariable 
analysis. These observations are consistent with highly protective effect of ART shown in the studies 
from settings with a high tuberculosis.15,16,18,31,34,39.  However, these factors were not associated with 
infection in multivariate analysis in our study, probably because of insufficient power. 
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Limitations 
There are several limitations to this study. First, we relied on the diagnosis of tuberculosis made by 
clinicians.  This is notoriously challenging in HIV-infected children, because of overlapping clinical 
presentations of HIV, tuberculosis and other comorbidities; difficulties with obtaining specimens; 
and difficulties with microbiological confirmation secondary to the paucibacillary nature of 
childhood tuberculosis. Tuberculosis diagnosis therefore might have been underestimated or 
overestimated. However, all cases were reviewed by an independent clinician, and a third of 
tuberculosis -related CDC classified events were reported as definitive, which is comparable to 
proportions confirmed in the general paediatric population. Secondly, we were unable to identify or 
rule out tuberculosis-associated-IRIS. Third, because of the small number of tuberculosis events, we 
could not assess whether children on suppressive ART with immune reconstitution were still at 
higher risk of incident tuberculosis compared with the general paediatric population.  Fourth, data 
for tuberculosis screening practice and preventive treatment over time and across clinics were not 
collected and could not be assessed.  
 
Conclusion 
Tuberculosis infection rates and case-fatality rates in HIV-infected children in the UK and Ireland are 
markedly higher than those reported in the general paediatric population, raising the important 
question of whether tuberculosis screening and prevention practices could be improved to avert 
morbidity and mortality in this population. Children at high risk of incident tuberculosis as identified 
by this study (older children, children of black African ethnic origin and those with severe 
immunosuppression) might benefit from repeat exposure-history and symptom-based screening 
during follow-up, and targeted preventive treatment.  Further studies to evaluate current screening 
and prevention practices and potential gaps in care are warranted.  
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Table 1: Patient characteristics at presentation to HIV care in the UK/ Ireland 
Characteristic (n=number with 
data available if not 
complete) 
TB at 
presentation  
(n=29) 
TB during 
follow-up* 
(n=28) 
No TB  
(n=1791) 
Overall 
(n=1848) 
p-value† 
 n (%) or median [interquartile range, IQR]  
Male  17 (59%) 15 (54%) 852 (48%) 901 (48%) 0·2023 
Age (years)†  7·0 [4·3, 10·5] 8·2 [5·8, 10·9] 4·8 [1·4, 9·0] 4·9 [1·5, 9·1] <0·0001 
     <5 years 11 (38%) 5 (18%) 920 (51%) 936 (51%) 0·0005 
Place of birth† (n=29, 28, 1781) 
0·0005      UK/Ireland 5 (17%) 6 (21%) 798 (45%) 809 (44%) 
     Abroad 24 (83%) 22 (79%)  983 (55%) 1029 (56%) 
         In high TB burden country 15 (63%) 16 (73%) 609 (62%) 640 (62%) 0·4572 
Region  
0·0848     London 20 (69%) 19 (68%) 1020 (57%) 1059 (57%) 
    Rest of UK/Ireland 9 (31%) 9 (32%) 771 (43%) 789 (43%) 
Ethnicity† (n=29, 28, 1778) 
0·0176 
     White 0 0 163 (9%)  164 (9%) 
     Black African 25 (86%) 26 (93%) 1396 (78%) 1447 (78%) 
     Asian/Middle 
East/Mixed/Other 
4 (14%) 2 (7%) 219 (12%) 238 (13%) 
Mode of presentation† 
0·0001      Pre-AIDS 15 (52%) 25 (89%) 1568 (88%) 1608 (87%) 
     AIDS  14 (48%) 3 (11%) 223 (12%) 240 (13%) 
Source of HIV infection (n=29, 28, 1752) 
0·4617 
    Perinatal 28 (97%) 28 (100%) 1699 (95%) 1755 (95%) 
    Blood transfusion 0 0 35 (2%) 35 (2%) 
    Other 1 (3%) 0 18 (1%) 19 (1%) 
CD4%, age <5 years (n=10, 4, 
746) 
21 [16, 27] 25 [9, 30] 24 [16, 33] 24 [16, 33] 0·2820 
CD4 count (cells per μL), age 
≥5 years (n=16, 20, 684) 
148 [35, 410] 273 [124, 542] 408 [200, 684] 400 [195, 673] 0·0055 
WHO immunological stage (n=28, 27, 1599) 
0·0761 
     None 4 (14%) 9 (32%) 568 (32%) 581 (31%) 
     Mild 5 (17%) 3 (11%) 237 (13%) 245 (13%) 
     Advanced 2 (7%) 3 (11%) 200 (11%) 205 (11%) 
     Severe 17 (59%) 12 (43%) 594 (33%) 623 (34%) 
Viral load (log 10) (n=29, 25, 
1436) 
5·1 [4·6, 5·6] 4·6 [4·0, 5·0] 4·7 [3·8, 5·3] 4·7 [3·8, 5·3] 0·4059 
Viral load <400 (copies per mL) 2 (7%)** 1 (4%) 133 (7%) 136 (7%) 0·4749 
ART prior to UK/Ireland HIV 
care† 
0 1 (4%) 197 (11%) 198 (11%) 0·0262 
* One patient who had TB at presentation to HIV care and during follow-up is summarised in the TB at 
presentation group 
** Started on ART shortly after presentation to HIV care, first available viral load after ART initiation and within 
window of 90 days after presentation  
† Comparison between those with TB at presentation/during follow-up vs those with no TB 
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Table 2:  Patient characteristics, sites of TB disease and ART status at time of TB diagnosis  
 *Intra- or extrathoracic  
**3 of those with TB at presentation and 1 with TB during follow-up who were not on ART at the time of diagnosis never 
received ART 
† Comparison between TB events at presentation and TB events during follow-up. 
  
Characteristic (n=number with data available if not 
complete)  
TB events at 
presentation 
(n=29) 
TB events during 
follow-up (n=29) 
Overall 
(n=58) p-value† 
 n (%) or median [IQR] (range)  
Age (years)†  6·9 [4·2, 10·4] 10·1 [8·6, 13·7] 9·3 [5·3, 12·3] 0·0110 
CD4%, age <5 years (n=11, 3) 19 [11, 27] 25 [15, 37] 21 [15, 27] 0·3918 
CD4 count (cells per μL), age≥5 years (n=18, 24)  148 [60, 398] 243 [160, 462] 228 [138, 442] 0·2857 
WHO immunological stage  (n=29, 27) 
0·2323 
   None 5 (17%) 5 (17%) 10 (17%) 
   Mild 5 (17%) 5 (17%) 10 (17%) 
   Advanced 2 (7%) 7 (24%) 9 (16%) 
   Severe 17 (59%) 10 (34%) 27 (47%) 
Viral load (log10)† (n=29, 26) 5·1 [4·6, 5·6] 3·7 [2·2, 4·5] 4·6 [2·7, 5·2] 0·0003 
Viral load <400 (copies per mL)† 2 (7%) 8 (28%) 10 (17%) 0·0346 
TB site 
Pulmonary only 11 (38%) 14 (48%) 25 (43%) 
0·5543 
Extrapulmonary with and without pulmonary 
involvement 
14 (48%) 10 (35%) 24 (41%) 
         TB meningitis  3 5 8 
         Miliary 5 0 5 
         Disseminated, site not specified 1 1 3 
         Osteoarticular  0 2 2 
         Abdomen 0 1 1 
         Lymph nodes* 2 0 2 
         Site not specified 1 1 1 
         Pulmonary and peripheral lymph nodes 1 0 1 
         Pulmonary and TB meningitis 1 0 1 
Unspecified 4 (14%) 5 (17%) 9 (16%) 
ART† 
ART naïve at TB diagnosis 29 (100%) 8 (28%) 37 (64%) 
<0·0001 
ART experienced but not on ART at time of TB 
diagnosis  
0 2 (7%) 2 (3%) 
    Time from TB diagnosis to ART initiation/restart** 
1·4 [0·5, 7·7]  
(0·1, 45·8) 
 7.6 [4·4, 25.2]  
(0·2, 74·0) 
2·9 [0·7, 13·7] 
(0·1, 74·0) 
On ART at time of TB diagnosis 0 19 (66%) 19 (33%) 
    Time from initiation of ART to TB diagnosis - 
14.3 [6·2, 44·0]  
(1·1, 110·0) 
14·3 [6·2, 44·0]  
(1·1, 110·0) 
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Table 3: Factors associated with TB diagnosis at presentation to HIV care 
 Univariable Multivariable 
Odds 
ratio 
95% CI p-value 
Odds 
ratio 
95% CI p-value 
Gender 
Male 1 - 
0·2409 - 
Female 0·64 0·31, 1·35 
Age (years) 
<5 0.77 0·31, 1·94 
0·1934 - 5–<10 1 - 
≥10 1·75 0·68, 4·47 
Place of birth 
Abroad 1 - 
0·0020 
1 - 
0·0036 
UK/Ireland 0·26 0·10, 0·69 0·28 0·10, 0·73 
Ethnicity 
Black African 1 - 
0·2730 - 
Other 0·57 0·20, 1·66 
Region 
London 1 - 
0·1932 - Rest of 
UK/Ireland 
0·60 0·27, 1·32 
Calendar year 
<2003 0·94 0·41, 2·20 
0·8842 - 2003–2006 1 - 
>2007 0·78 0·27, 2·20 
WHO 
immunological 
stage 
None 0·25 0·08, 0·74 
0·0315 
0·25 0·08, 0·74 
0·0331 
Mild 0·74 0·27, 2·04 0·73 0·26, 1·99 
Advanced 0·35 0·08, 1·53 0·36 0·08, 1·60 
Severe 1 - 1 - 
Viral load, per 0.5 log10 increase 1·10 0·93, 1·29 0·2522 - 
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Table 4: Factors associated with TB diagnosis during follow-up  
 Numbe
r of 
cases 
Crude rate per 
100000 PY  
(95% CI) 
Univariable Multivariable 
Hazard 
ratio 
95% CI p-value 
Hazard 
ratio 
95% CI p-value 
Overall 29 196 (137, 283) - 
Baseline (presentation to HIV care) 
Gender 
Male 15 210 (128, 349) 1 - 
0·6765 - 
Female 14 184 (109, 310) 0·86 0·41, 1·77 
Age (years) 
<5 6 63 (29, 140) 0·20 0·08, 0·53 
0·0004 
0·20 0·08, 0·53 
0·0027 5–<10 15 392 (238, 654) 1 - 1 - 
≥10 8 557 (279, 1114) 1·12 0·46, 2·71 1·11 0·47, 2·63 
Place of birth 
Abroad  22 330 (217, 502) 1 - 
0·0070 - 
UK/Ireland 7 87 (41, 182) 0·34 0·13, 0·79 
Ethnicity 
Black African 27 247 (169, 360) 1 - 
0·0169 
1 - 
0·0895 
Other 2 52 (13, 209) 0·24 0·06, 1·01 0·34 0·08, 1·44 
Region 
London 19 210 (134, 330) 1 - 
0·4359 - Rest of 
UK/Ireland 
10 175 (94, 324) 0·74 0·34, 1·60 
Mode of 
presentation 
Pre-AIDS 26 202 (137, 296) 1 - 
0·7571 - 
AIDS 3 160 (51, 495) 0·83 0·25, 2·75 
Calendar year 
<2003 12 126 (72, 222) 0·50 0·23, 1·10 
0·2006 - 2003–2006  13 356 (207, 613) 1 - 
>2007 4 249 (94, 665) 0·53 0·17, 1·65 
WHO 
immunological 
stage 
None 9 198 (103, 380) 0·78 0·33, 1·86 
0·8301 - 
Mild 3 146 (47, 452) 0·59 0·17, 2·10 
Advanced 4 244 (92, 651) 0·98 0·32, 3·04 
Severe 12 248 (141, 437) 1 - 
ART status 
Naïve 28 204 (141, 295) 1 - 
0·2653 - 
Experienced 1 97 (14, 689) 0·38 0·05, 2·79 
Viral load, per 0.5 log10 increase - 0·98 0·83, 1·15 0·7721 - 
Time-updated variables 
Age (years) 
<5 3 118 (38, 365) 0·32 0·08, 1·18 
0·0087 - 5–<10 10 203 (109, 378) 1 - 
≥10 16 219 (134, 358) 1·82 0·82, 4·03 
Calendar year 
<2003 6 166 (75, 371) 0·44 0·16, 1·20 
0·2479 - 2003–2006 11 296 (164, 535) 1 - 
>2007 12 161 (92, 284) 0·78 0·34, 1·80 
WHO 
immunological 
stage 
None 7 76 (36, 159) 0·13 0·05, 0·35 
0·0001 
0·15 0·06, 0·41 
0·0056 
Mild 6 250 (113, 557) 0·45 0·16, 1·25 0·44 0·16, 1·20 
Advanced 6 498 (224, 1109) 0·90 0·33, 2·48 0·85 0·31, 2·34 
Severe 10 552 (297, 1026) 1 - 1 - 
ART status 
Off ART 10  225 (121, 417) 1 - 
0·0656 - 
On ART <4 
months 
6  990 (445, 2204) 3·24 1·08, 9·67 
On ART 4–12 
months 
5 414 (172, 995) 1·61 0·52, 4·95 
On ART >12 
months 
8 94 (47, 188) 0·57 0·22, 1·52 
Viral load 
(copies per mL) 
≥400 20 304 (196, 471) 1 - 
0·0161 - 
<400 9 122 (63, 234) 0·40 0·18, 0·87 
Viral load, per 0.5 log10 increase - 1·51 1·16, 1·98 0·0020 - 
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